Skip to content
Open access

Divergent amyloid trajectories distinguish normal aging from Alzheimer's disease progression

Sep 2026 · bioRxiv · 0 citations · 44 references
Medicine Biology

TL;DR

This work model AD progression as a deviation from aging using longitudinal amyloid PET and a self-supervised trajectory-learning framework and reveals a shared early path that bifurcated into an aging branch and an AD-related branch.

Abstract

Aging is the greatest risk factor for Alzheimer’s disease (AD), yet how and when AD-related pathological progression diverges from aging remains poorly understood. This distinction is particularly difficult at early stages, when clinically and biomarker-defined populations contain individuals following fundamentally different trajectories. Here, we model AD progression as a deviation from aging using longitudinal amyloid PET and a self-supervised trajectory-learning framework. In ADNI, the learned trajectory revealed a shared early path that bifurcated into an aging branch and an AD-related branch. The two branches showed distinct profiles in amyloid burden, cognitive decline, risk of progression to AD dementia, and genetic risk. Unseen participants from the independent NACC cohort were projected onto the trajectory without retraining, further reproducing key branch-specific biological and genetic patterns. Together, the bifurcating trajectory provides a biologically grounded framework for resolving early-stage heterogeneity and enabling risk stratification beyond binary amyloid status.

Read PDF

Similar papers

Sep 2026

Joint impact of pathological burden and cognitive resilience on Alzheimer's disease risk.

The findings broaden the understanding that AD dementia is shaped jointly by pathological burden and cognitive resilience, and argue for therapeutic trial and prevention strategies that strengthen resilience alongside reducing pathology.

Zhi-Bo Wang, Shu-Heng Wang, Yu-Mei Liang et al. · 1 citation
Open access Aug 2026

Alzheimers disease blood biomarkers reveal proteomic modules of disease progression

Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.

R. R. Butler, M. Brown, A. Weber et al. · 1 citation
Aug 2026

Deep multimodal clustering identifies biological subtypes of normal aging with divergent cognitive decline risk

The study reveals marked variability among individuals who are otherwise all defined as cognitively normal, and provides a data-driven stratification framework for enriching disease-modifying and preventive trials by identifying cognitively normal individuals at high risk for future cognitive decline.

M. M. Diaz, E. Dayan · 0 citations
Open access Sep 2026

Beyond statistical thresholds: Mapping sequential ATN cascade transitions via brain structural topography in Alzheimer’s disease

Alzheimer’s disease is widely conceptualized as a biological continuum initiated by amyloid-β (Aβ) accumulation, followed by tau aggregation and neurodegeneration. Although the ATN framework is commonly used to define disease stages, its static biomarker categories may not fully capture the dynamic pathological transit...

Dong Wang, Shao-Zhen Yan, Rong-Shen Zhou et al. · 0 citations
Review Sep 2026

Atypical Alzheimer disease: a multi-axis framework toward defining heterogeneity.

A practical multi-axis framework comprising clinical phenotype, AD biological context (AD pathology plus co-pathologies and molecular modifiers), network topography (regional patterns) and tempo (rate of clinical and biomarker progression) is proposed to reduce diagnostic mismatches, make cohorts more comparable and su...

L. Grinberg, M. Murray · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.